Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Name: Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Download Sample Buy Report

Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Report 2025

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 - By Type (Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types), By Indication (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Specialty Clinics, Research Institutions, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : April 2025 | Delivery Time: 2-3 business days Info | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Proud Members Of

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a group of drugs mainly used in cancer therapy. These medications work by blocking DNA repair in cancer cells, particularly in cancers with BRCA mutations. They are commonly used to treat ovarian and Breast Cancer and are usually taken orally. PARP inhibitors help reduce the risk of cancer returning after chemotherapy and can cause side effects such as fatigue and low blood cell counts.

The main types of poly(ADP-ribose) polymerase (PARP) inhibitors include olaparib, rucaparib, niraparib, talazoparib, and other types. Olaparib is a PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers by preventing DNA repair in cancer cells, leading to cell death. These drugs are used for various indications, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used by various end-users, including hospitals, specialty clinics, research institutions, and others.

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Size and growth rate 2025 to 2029: Graph

What Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Size 2025 And Growth Rate?

The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to increasing cancer incidence, increasing genetic testing, increasing success in clinical trials, growing insurance coverage, and growth in cancer research.

What Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Forecast?

The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising production and supply of drugs, the growing prevalence of BRCA-mutated cancers, the rising prevalence of breast cancer, the growing use of monoclonal antibodies, and the rising healthcare expenditure. Major trends in the forecast period include advancements in biomarker research, combination therapies, integration of artificial intelligence in drug development, advancements in biomarker-driven therapy, and development of next-generation PARP inhibitors.

Book your 30 minutes free consultation with our research experts

How Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmented?

The poly(ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –

1) By Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types

2) By Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Olaparib: BRCA-Mutated Cancers, HRD-Positive Cancers, Maintenance Therapy

2) By Rucaparib: Ovarian Cancer, Prostate Cancer, Pancreatic Cancer

3) By Niraparib: First-Line Treatment, Recurrent Cancer Treatment, Late-Stage Cancer

4) By Talazoparib: Breast Cancer, Germline BRCA-Mutated Tumors, Neoadjuvant Or Adjuvant Therapy

5) By Other Types: Emerging PARP Inhibitors, Investigational Therapies, Novel Combinations

What Is Driving The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Rising Prevalence Of Breast Cancer Fueling The Growth Of The Market Due To Increasing Demand For Targeted Cancer Therapies

The rising prevalence of breast cancer is expected to propel the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market going forward. Breast cancer refers to a disease in which cells in the breast grow uncontrollably, forming a malignant tumor that can spread to other parts of the body. The rising prevalence of breast cancer is attributed to factors such as aging populations, lifestyle changes, genetic predisposition, hormonal imbalances, obesity, alcohol consumption, and increasing exposure to environmental risk factors. PARP inhibitors help breast cancer patients by blocking the PARP enzyme's ability to repair DNA damage in cancer cells, leading to cell death, particularly in tumors with BRCA1 or BRCA2 mutations. For instance, in January 2025, according to the National Breast Cancer Foundation, a US-based organization, one in every eight women in the United States will be diagnosed with breast cancer during her lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. Therefore, the rising prevalence of breast cancer is driving the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

Who Are The Major Players In The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.

What Are The Key Trends Of The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Advancements In Targeted Cancer Therapies Driving Innovation In PARP Inhibitors

Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are focusing on developing advanced cancer treatments, such as anticancer medicines, to target specific genetic mutations prevalent in certain cancers. Anticancer medicines are drugs used to treat cancer by inhibiting the growth of cancer cells, preventing their spread, or destroying them. These medicines work through various mechanisms, including interfering with cell division, blocking specific proteins essential for tumor growth, or stimulating the immune system to fight cancer. For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched IBYRA, a generic version of the PARP inhibitor olaparib, in India. The drug provides an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers. It significantly reduces treatment costs compared to the innovator drug.

What Are Latest Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Ariceum Therapeutics Expands Pipeline With Acquisition Of Theragnostics Ltd. To Advance Radio-Labeled PARP Inhibitors For Cancer Theranostics

In June 2023, Ariceum Therapeutics GmbH, a Germany-based biotechnology company, acquired Theragnostics Ltd. for an undisclosed amount. With this acquisition, Ariceum Therapeutics aims to expand its radiopharmaceutical pipeline by integrating Theragnostics' next-generation PARP inhibitor radiation therapies and strengthening its U.S. operations. Theragnostics Ltd is a UK-based biopharmaceutical company that specializes in developing radio-labeled PARP inhibitors.

What Is The Regional Outlook For The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly(ADP-ribose) polymerase (PARP) inhibitors market consists of sales of rubraca, zejula, and talzenna. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

The poly (ADP-Ribose) polymerase (PARP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides poly (ADP-Ribose) polymerase (PARP) inhibitors market statistics, including the poly (ADP-Ribose) polymerase (PARP) inhibitors industry global market size, regional shares, competitors with the poly (ADP-Ribose) polymerase (PARP) inhibitors market share, detailed poly (ADP-Ribose) polymerase (PARP) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the poly (ADP-Ribose) polymerase (PARP) inhibitors industry. This poly (ADP-Ribose) polymerase (PARP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

PolyADP Ribose Polymerase PARP Inhibitors Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$7.56 billion
Revenue Forecast In 2034	$13.45 billion
Growth Rate	CAGR of 15.5% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The poly(ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented – 1) By Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types 2) By Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Other End-Users Subsegments: 1) By Olaparib: BRCA-Mutated Cancers, HRD-Positive Cancers, Maintenance Therapy 2) By Rucaparib: Ovarian Cancer, Prostate Cancer, Pancreatic Cancer 3) By Niraparib: First-Line Treatment, Recurrent Cancer Treatment, Late-Stage Cancer 4) By Talazoparib: Breast Cancer, Germline BRCA-Mutated Tumors, Neoadjuvant Or Adjuvant Therapy 5) By Other Types: Emerging PARP Inhibitors, Investigational Therapies, Novel Combinations
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Characteristics

3. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends And Strategies

4. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Rate Analysis

5.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Total Addressable Market (TAM)

6. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmentation

6.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Olaparib

Rucaparib

Niraparib

Talazoparib

Other Types

6.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ovarian Cancer

Breast Cancer

Prostate Cancer

Pancreatic Cancer

6.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Research Institutions

Other End-Users

6.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

BRCA-Mutated Cancers

HRD-Positive Cancers

Maintenance Therapy

6.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ovarian Cancer

Prostate Cancer

Pancreatic Cancer

6.7. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

First-Line Treatment

Recurrent Cancer Treatment

Late-Stage Cancer

6.8. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer

Germline BRCA-Mutated Tumors

Neoadjuvant Or Adjuvant Therapy

6.9. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Emerging PARP Inhibitors

Investigational Therapies

Novel Combinations

7. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional And Country Analysis

7.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

8.1. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

9.1. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

9.2. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

10.1. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

11.1. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

11.2. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

12.1. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

13.1. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

14.1. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

14.2. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

15.1. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

15.2. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

16.1. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

17.1. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

18.1. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

19.1. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

20.1. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

21.1. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

21.2. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

22.1. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

23.1. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

23.2. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

24.1. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

24.2. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

25.1. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

25.2. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

26.1. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

26.2. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

27.1. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

28.1. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

28.2. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

29.1. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

29.2. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape And Company Profiles

30.1. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape

30.2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. Bristol-Myers Squibb Company

31.3. GSK plc

31.4. Takeda Pharmaceutical Company Limited

31.5. Boehringer Ingelheim

31.6. Vertex Pharmaceuticals Inc.

31.7. Jiangsu Hengrui Pharmaceuticals Co. Ltd.

31.8. BeiGene LTD

31.9. Karyopharm Therapeutics Inc.

31.10. Clovis Oncology Inc.

31.11. Repare Therapeutics Inc.

31.12. Ribon Therapeutics

31.13. Artios Pharma

31.14. IMPACT Therapeutics Inc.

31.15. BiPar Sciences Inc.

32. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

34. Recent Developments In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

35. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market High Potential Countries, Segments and Strategies

35.1 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Countries Offering Most New Opportunities

35.2 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Segments Offering Most New Opportunities

35.3 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Pfizer Inc. Financial Performance

Table 81: Johnson & Johnson Services Inc. Financial Performance

Table 82: AbbVie Inc. Financial Performance

Table 83: Merck & Co. Inc. Financial Performance

Table 84: Bayer AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Pfizer Inc. Financial Performance

Figure 81: Johnson & Johnson Services Inc. Financial Performance

Figure 82: AbbVie Inc. Financial Performance

Figure 83: Merck & Co. Inc. Financial Performance

Figure 84: Bayer AG Financial Performance

How is the Allergy Diagnostics Market Poised for Growth: Trends and Opportunities Through 2034

Future Outlook of the Ambulatory Electronic Medical Records Market: Growth, Trends, and Emerging Opportunities Explored

Antimicrobial Susceptibility Testing Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Assisted Reproductive Technology Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

How is the Bed Monitoring System & Baby Monitoring System Market Poised for Growth: Trends and Opportunities Through 2034

Growth Opportunities and Trends in the Biopharmaceutical CMO Market: Key Insights for 2025-2034

How Will the Bipolar Disorder Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

Key Trends and Insights into the Bleeding Disorders Treatment Market: Growth Rate and Opportunities to 2034

HER2 Inhibitors Global Market Report 2025 – By Treatment (Monotherapy, Combination Therapy), By Application (Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications), By End User (Hospitals, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Checkpoint Inhibitors Global Market Report 2025 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications), By End-Users (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Protein Inhibitors Global Market Report 2025 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

TNF Alpha Inhibitors Global Market Report 2025 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Interleukin Inhibitors Global Market Report 2025 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6, Other Types), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

ACE Inhibitors Global Market Report 2025 – By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications), By End-Users (Hospitals, Online Drug Stores, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025 – By Product (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications), By End-Users (Hospitals, Specialty Clinics, Academic and Research Institutions) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Proton Pump Inhibitors Global Market Report 2025 – By Type (Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Dexlansoprazole, Other Types), By Disease Allocation (Ulcers, Gastroesophageal Reflux Disease, Other Disease Indications), By Application (Hospitals, Clinic, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market?

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a group of drugs mainly used in cancer therapy. These medications work by blocking DNA repair in cancer cells, particularly in cancers with BRCA mutations. They are commonly used to treat ovarian and breast cancer and are usually taken orally. PARP inhibitors help reduce the risk of cancer returning after chemotherapy and can cause side effects such as fatigue and low blood cell counts. For further insights on the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here

How will the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market drivers and restraints affect the market dynamics? What forces will shape the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors industry going forward?

The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market major growth driver - Rising Prevalence Of Breast Cancer Fueling The Growth Of The Market Due To Increasing Demand For Targeted Cancer Therapies. For further insights on the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here

What is the forecast market size or the forecast market value of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market?

The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market size has grown strongly in recent years. The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to increasing cancer incidence, increasing genetic testing, increasing success in clinical trials, growing insurance coverage, and growth in cancer research. The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising production and supply of drugs, the growing prevalence of BRCA-mutated cancers, the rising prevalence of breast cancer, the growing use of monoclonal antibodies, and the rising healthcare expenditure. Major trends in the forecast period include advancements in biomarker research, combination therapies, integration of artificial intelligence in drug development, advancements in biomarker-driven therapy, and development of next-generation PARP inhibitors. For further insights on the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here

How is the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market segmented?

The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market covered in this report is segmented –
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations For further insights on the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here

Which region has the largest share of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market? What are the other regions covered in the report?

Who are the major players in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market?

What are the key trends in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market?

Major trends in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market include Advancements In Targeted Cancer Therapies Driving Innovation In PARP Inhibitors. For further insights on the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here.

What are the major opportunities in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market? What are the strategies for the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market?

For detailed insights on the major opportunities and strategies in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market, request a sample here.

How does the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market relate to the overall economy and other similar markets?

For detailed insights on Poly(ADP-Ribose) Polymerase (PARP) Inhibitors's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors industry?

For detailed insights on the mergers and acquisitions in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors industry, request a sample here.

What are the key dynamics influencing the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market growth? SWOT analysis of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market.

For detailed insights on the key dynamics influencing the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors market growth and SWOT analysis of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors industry, request a sample here.

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Market Insights

Related Reports

What Is Covered Under Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

What Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Size 2025 And Growth Rate?

What Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Forecast?

How Is The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmented?

What Is Driving The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Rising Prevalence Of Breast Cancer Fueling The Growth Of The Market Due To Increasing Demand For Targeted Cancer Therapies

Who Are The Major Players In The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

What Are The Key Trends Of The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Advancements In Targeted Cancer Therapies Driving Innovation In PARP Inhibitors

What Are Latest Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market? Ariceum Therapeutics Expands Pipeline With Acquisition Of Theragnostics Ltd. To Advance Radio-Labeled PARP Inhibitors For Cancer Theranostics

What Is The Regional Outlook For The Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

What Defines the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

Table Of Contents

List Of Tables

List Of Figures

How is the Allergy Diagnostics Market Poised for Growth: Trends and Opportunities Through 2034

Future Outlook of the Ambulatory Electronic Medical Records Market: Growth, Trends, and Emerging Opportunities Explored

Antimicrobial Susceptibility Testing Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Assisted Reproductive Technology Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

How is the Bed Monitoring System & Baby Monitoring System Market Poised for Growth: Trends and Opportunities Through 2034

Growth Opportunities and Trends in the Biopharmaceutical CMO Market: Key Insights for 2025-2034

How Will the Bipolar Disorder Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

Key Trends and Insights into the Bleeding Disorders Treatment Market: Growth Rate and Opportunities to 2034

Frequently Asked Questions